Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 7
2012 10
2013 11
2014 5
2015 9
2016 8
2017 4
2018 5
2019 8
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

57 results
Results by year
Filters applied: . Clear all
Page 1
Prevention of transfusion-transmitted infections.
Busch MP, Bloch EM, Kleinman S. Busch MP, et al. Blood. 2019 Apr 25;133(17):1854-1864. doi: 10.1182/blood-2018-11-833996. Epub 2019 Feb 26. Blood. 2019. PMID: 30808637 Review.
Subsequently, progressive implementation of nucleic acid-amplification technology (NAT) screening for HIV, HCV, and HBV has reduced the residual risk of infectious-window-period donations, such that per unit risks are <1 in 1 000 000 in the United States, other h …
Subsequently, progressive implementation of nucleic acid-amplification technology (NAT) screening for HIV, HCV, and HBV has reduced the resi …
Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutiérrez L. Salunkhe V, et al. Transfus Apher Sci. 2015 Feb;52(1):19-34. doi: 10.1016/j.transci.2014.12.016. Epub 2014 Dec 30. Transfus Apher Sci. 2015. PMID: 25620756 Review.
While the use of pathogen reduction treatments in platelets is performed routinely in a fair number of European blood banks, most of these treatments are not (or just) licensed in the USA or elsewhere in the world. ...
While the use of pathogen reduction treatments in platelets is performed routinely in a fair number of European blood banks, most of these t …
Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.
Dean CL, Maier CL, Chonat S, Chang A, Carden MA, El Rassi F, McLemore ML, Stowell SR, Fasano RM. Dean CL, et al. Transfusion. 2019 May;59(5):1698-1705. doi: 10.1111/trf.15227. Epub 2019 Mar 8. Transfusion. 2019. PMID: 30848512
Patients who require episodic transfusions during heightened inflammatory states, such as patients with sickle cell disease (SCD), are particularly prone to alloimmunization and developing DHTRs with hyperhemolysis. ...
Patients who require episodic transfusions during heightened inflammatory states, such as patients with sickle cell disease (SCD), ar …
Will pathogen reduction of blood components harm more people than it helps in developed countries?
Hess JR, Pagano MB, Barbeau JD, Johannson PI. Hess JR, et al. Transfusion. 2016 May;56(5):1236-41. doi: 10.1111/trf.13512. Transfusion. 2016. PMID: 27167359 Review.
RESULTS: Transfusion-transmitted infectious diseases caused five or fewer acute deaths each year from 2009 through 2014 in the United States according to the Food and Drug Administration. ...
RESULTS: Transfusion-transmitted infectious diseases caused five or fewer acute deaths each year from 2009 through 2014 in the United
Immunoregulatory networks in sickle cell alloimmunization.
Yazdanbakhsh K. Yazdanbakhsh K. Version 2. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):457-461. doi: 10.1182/asheducation-2016.1.457. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913516 Free PMC article. Review.
57 results
Jump to page
Feedback